Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 10, 2013

Denovo Partners with ALS Nonprofit to ID Biomarkers

  • The ALS Emergency Treatment Fund (ALS-ETF) and Denovo Biomarkers are partnering in a pharmacogenomics-based effort to identify potential responder groups for drugs being studied in amyotrophic lateral sclerosis patients.

    Through this partnership, the firms will use Denovo technology to analyze samples obtained from expanded access programs that ALS-ETF sponsors with the hopes of identifying genomic biomarkers that correlate with treatment response, the firms said. Financial terms of the agreement were not disclosed.

    In a statement, Denovo CSO Wen Luo noted: "This partnership leverages the mission of ALS-ETF and the broad utility of our platform. We hope that our combined efforts will lead to better, more targeted treatments for ALS."



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »